Hideaki Yamana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hideaki Yamana has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
H Fujita
5 shared publicationsT Fujii
Dept. of Surgery, Kurume University School of Medicine, Kurume University Research Center for Innovative Cancer Therapy
5 shared publicationsT. Fujii
5 shared publicationsU. Toh
5 shared publicationsE. Ogo
4 shared publicationsK. Shirouzu
4 shared publications
Latest Publications
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , TPS173
A phase II study of personalized selection of peptide vaccines combined with conventional chemo- or endocrine therapy for refractory breast cancer.
TPS173 Background: Immunotherapy using selected personalized peptide vaccines (PPV) has been reported to be effective for boosting anticancer immunity in many patients (pts) even in an advanced status. This study evaluate the anti-tumor immunologic effect and safety of PPV for pts with refractory breast cancer. Methods: Patient eligibility criteria: all patients had histologically confirmed measurable metastatic breast cancer and their HLA A molecules should be each of HLA-A2, A3, A11, A24, A26, A31 or A33. The following criteria were also required: age > 20 years, life expectancy of at least 3 months, ECOG performance status of 0 or 1, adequate vital organ function (WBC > 2,500/μ L; platelets > 80,000/μ L; serum creatinine < 1.5 mg/dL or creatinine clearance > 50 mL/min; AST and ALT < 2 times the upper limit of the institution's normal range; and total bilirubin < 2.5 mg/dL. All subjects provided written informed consent and the clinical protocol was approved by each institutional review board before patient enrollment. Treatment schedule:Pre- vaccination plasma was measured for their IgG levels reactive to each of the previously reported 31 candidate peptides followed by administration subcutaneously of the four peptides at maximum showing higher levels of IgG in order with schedule of every 1-2 week for a total of 6-24 doses. The concurrent conventional chemotherapy or endocrine therapy was available for the combination of PPV. Study design: This is an open-label, multicenter, single-arm, phase II study. The primary endpoint was anti-tumor immunologic effect and safety, and the secondary endpoints were clinical responses. The planned sample size was 60-80. Immune and clinical response assessment : Levels of IgG reactive to each of the 31 peptides in the pre- and post-treatment plasma at every 6 times of vaccination were measured using LUMNEX system. Clinical response was evaluated by RECIST criteria. Correlation between overall survival and the increased IgG levels was also investigated. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , TPS173
A phase II study of personalized selection of peptide vaccines combined with conventional chemo- or endocrine therapy for refractory breast cancer.
TPS173 Background: Immunotherapy using selected personalized peptide vaccines (PPV) has been reported to be effective for boosting anticancer immunity in many patients (pts) even in an advanced status. This study evaluate the anti-tumor immunologic effect and safety of PPV for pts with refractory breast cancer. Methods: Patient eligibility criteria: all patients had histologically confirmed measurable metastatic breast cancer and their HLA A molecules should be each of HLA-A2, A3, A11, A24, A26, A31 or A33. The following criteria were also required: age > 20 years, life expectancy of at least 3 months, ECOG performance status of 0 or 1, adequate vital organ function (WBC > 2,500/μ L; platelets > 80,000/μ L; serum creatinine < 1.5 mg/dL or creatinine clearance > 50 mL/min; AST and ALT < 2 times the upper limit of the institution's normal range; and total bilirubin < 2.5 mg/dL. All subjects provided written informed consent and the clinical protocol was approved by each institutional review board before patient enrollment. Treatment schedule:Pre- vaccination plasma was measured for their IgG levels reactive to each of the previously reported 31 candidate peptides followed by administration subcutaneously of the four peptides at maximum showing higher levels of IgG in order with schedule of every 1-2 week for a total of 6-24 doses. The concurrent conventional chemotherapy or endocrine therapy was available for the combination of PPV. Study design: This is an open-label, multicenter, single-arm, phase II study. The primary endpoint was anti-tumor immunologic effect and safety, and the secondary endpoints were clinical responses. The planned sample size was 60-80. Immune and clinical response assessment : Levels of IgG reactive to each of the 31 peptides in the pre- and post-treatment plasma at every 6 times of vaccination were measured using LUMNEX system. Clinical response was evaluated by RECIST criteria. Correlation between overall survival and the increased IgG levels was also investigated. No significant financial relationships to disclose.
- Open Access
- 1 March 2010
- Published by IOP Publishing in IOP Conference Series: Materials Science and Engineering
- Vol. 9 (1) , 012050
Electronic absorption spectra of U3+and U4+in molten LiCl-RbCl eutectic
In the non-aqueous reprocessing process of spent nuclear fuels by the pyro-electrochemical method, a spent fuel is dissolved into molten LiCl-KCl and NaCl-CsCl eutectics and dissolved uranium and plutonium are collected as either metal or oxide. However, the binary alkali chloride mixture with the lowest melting point is the LiCl-RbCl eutectic. In this study, electronic absorption spectra of U3+ and U4+ in molten LiCl-RbCl eutectic at various temperatures between 673 and 973 K were measured by the UV/Vis/NIR spectrophotometry. We confirmed that these spectra were similar to those in molten LiCl-KCl and NaCl-CsCl eutectics. The sensitive absorption bands of U4+ in LiCl-RbCl eutectic were found at 22000, 16500, 14900, 8600, and 4950 cm−1. The large absorption bands of U4+ over 25000 cm−1 increased with increasing melt temperature, while absorption peaks at 15500-4000 cm−1 decreased. The large absorption bands of U3+ in LiCl-RbCl eutectic were observed over 14000 cm−1. The sensitive absorption bands of U3+ at Vis/NIR region were found at 13300, 11500-11200, 9800-9400, and 8250 cm−1, and these peaks decreased with increasing temperature.
- 1 March 2010
- Published by IOP Publishing in IOP Conference Series: Materials Science and Engineering
- Vol. 9 (1) , 012050
Open AccessElectronic absorption spectra of U3+and U4+in molten LiCl-RbCl eutectic
In the non-aqueous reprocessing process of spent nuclear fuels by the pyro-electrochemical method, a spent fuel is dissolved into molten LiCl-KCl and NaCl-CsCl eutectics and dissolved uranium and plutonium are collected as either metal or oxide. However, the binary alkali chloride mixture with the lowest melting point is the LiCl-RbCl eutectic. In this study, electronic absorption spectra of U3+ and U4+ in molten LiCl-RbCl eutectic at various temperatures between 673 and 973 K were measured by the UV/Vis/NIR spectrophotometry. We confirmed that these spectra were similar to those in molten LiCl-KCl and NaCl-CsCl eutectics. The sensitive absorption bands of U4+ in LiCl-RbCl eutectic were found at 22000, 16500, 14900, 8600, and 4950 cm−1. The large absorption bands of U4+ over 25000 cm−1 increased with increasing melt temperature, while absorption peaks at 15500-4000 cm−1 decreased. The large absorption bands of U3+ in LiCl-RbCl eutectic were observed over 14000 cm−1. The sensitive absorption bands of U3+ at Vis/NIR region were found at 13300, 11500-11200, 9800-9400, and 8250 cm−1, and these peaks decreased with increasing temperature.
- Open Access
- 1 March 2010
- Published by IOP Publishing in IOP Conference Series: Materials Science and Engineering
- Vol. 9 (1) , 012069
Am/Cm separation in molten chloride melt utilizing the divalency of Am
In order to establish a new technique to separate americium from curium and lanthanides in the treatment process of High Active Waste, the feasibility of the separation of Am by reduction to divalent state in chloride melts was studied. As a homologue of the formation of divalent Am and its reaction, electrochemical measurements and electrolysis of Nd were conducted using the LiCl-KCl eutectic melt. Based on the reported formal potentials and the thermodynamic values of the compound of related elements, the feasibility of the Am separation was evaluated. As a result, a rough concept of the new process to be attached to the downstream of the aqueous reprocessing process was proposed.
- 1 March 2010
- Published by IOP Publishing in IOP Conference Series: Materials Science and Engineering
- Vol. 9 (1) , 012069
Open AccessAm/Cm separation in molten chloride melt utilizing the divalency of Am
In order to establish a new technique to separate americium from curium and lanthanides in the treatment process of High Active Waste, the feasibility of the separation of Am by reduction to divalent state in chloride melts was studied. As a homologue of the formation of divalent Am and its reaction, electrochemical measurements and electrolysis of Nd were conducted using the LiCl-KCl eutectic melt. Based on the reported formal potentials and the thermodynamic values of the compound of related elements, the feasibility of the Am separation was evaluated. As a result, a rough concept of the new process to be attached to the downstream of the aqueous reprocessing process was proposed.
- 1 March 2010
- Published by IOP Publishing in IOP Conference Series: Materials Science and Engineering
- Vol. 9 (1) , 012061
Study on coordination characteristics of neptunium and uranium ions in calcium nitrate hydrate melt by Raman spectrometry and UV/Vis/NIR spectrometry
Extraction behavior of neptunium (Np) by tri-n-butyl phosphate from calcium nitrate hydrate melt was investigated. Distribution ratio of Np was found to increase with the decrease of water content. Adding nitric acid into the system resulted in an increase of the distribution ratio. In order to understand the extraction trends, Np species in the hydrate melt were analyzed by Raman spectrometry and UV/Vis/NIR spectrometry. Major fraction was assigned to be NpO22+ of Np(VI) and small fraction to be NpO2+ of Np(V). A shift of the v1 symmetric vibrational frequency of NpO22+ in nitrate media was found in Raman spectra. This suggests a coordination circumstance change of NpO22+.
- 1 March 2010
- Published by IOP Publishing in IOP Conference Series: Materials Science and Engineering
- Vol. 9 (1) , 012061
Study on coordination characteristics of neptunium and uranium ions in calcium nitrate hydrate melt by Raman spectrometry and UV/Vis/NIR spectrometry
Extraction behavior of neptunium (Np) by tri-n-butyl phosphate from calcium nitrate hydrate melt was investigated. Distribution ratio of Np was found to increase with the decrease of water content. Adding nitric acid into the system resulted in an increase of the distribution ratio. In order to understand the extraction trends, Np species in the hydrate melt were analyzed by Raman spectrometry and UV/Vis/NIR spectrometry. Major fraction was assigned to be NpO22+ of Np(VI) and small fraction to be NpO2+ of Np(V). A shift of the v1 symmetric vibrational frequency of NpO22+ in nitrate media was found in Raman spectra. This suggests a coordination circumstance change of NpO22+.
- Open Access
- 1 March 2010
- Published by IOP Publishing in IOP Conference Series: Materials Science and Engineering
- Vol. 9 (1) , 012080
Electrochemical characteristics of uranium ions in calcium chloride hydrate melts
Redox reactions of tetravalent uranium ion in calcium chloride hexahydrate CaCl 2 •6H 2 O melt ([CaCl 2 ] = 6.9 M) were studied electrochemically and spectrophotometrically. Cyclic voltammograms in CaCl 2 •6H 2 O melt containing UCl 4 were measured with a pyrographite carbon working electrode. A cathodic peak corresponding to the reduction of U 4+ to U 3+ was observed, and it was found to be controlled by the diffusion of U 4+ in the melt. Although the concentration of H + in the melt was negligible, the redox reaction of U 4+ was observed without the disturbance of hydrolysis. The formal potential of the U 4+ |U 3+ couple was determined to be-0.483 ± 0.005 V vs. NHE. The diffusion coefficient of U 4+ in CaCl 2 •6H 2 O melt was determined to be 1.5 × 10-7 cm 2 s-1 at 300 K. The anodic peak in the voltammogram was attributable to the oxidation of U 4+ to UO 2 2+ , which was identified by using a technique based on the combination of electrolysis and spectrophotometry. Influences of the water content on chemical status of uranium ions in CaCl 2 hydrate melts were studied.
- 1 March 2010
- Published by IOP Publishing in IOP Conference Series: Materials Science and Engineering
- Vol. 9 (1) , 012080
Open AccessElectrochemical characteristics of uranium ions in calcium chloride hydrate melts
Redox reactions of tetravalent uranium ion in calcium chloride hexahydrate CaCl 2 •6H 2 O melt ([CaCl 2 ] = 6.9 M) were studied electrochemically and spectrophotometrically. Cyclic voltammograms in CaCl 2 •6H 2 O melt containing UCl 4 were measured with a pyrographite carbon working electrode. A cathodic peak corresponding to the reduction of U 4+ to U 3+ was observed, and it was found to be controlled by the diffusion of U 4+ in the melt. Although the concentration of H + in the melt was negligible, the redox reaction of U 4+ was observed without the disturbance of hydrolysis. The formal potential of the U 4+ |U 3+ couple was determined to be-0.483 ± 0.005 V vs. NHE. The diffusion coefficient of U 4+ in CaCl 2 •6H 2 O melt was determined to be 1.5 × 10-7 cm 2 s-1 at 300 K. The anodic peak in the voltammogram was attributable to the oxidation of U 4+ to UO 2 2+ , which was identified by using a technique based on the combination of electrolysis and spectrophotometry. Influences of the water content on chemical status of uranium ions in CaCl 2 hydrate melts were studied.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 3062
Strategy to augment the efficacy of immunotherapy for refractory breast cancer using trastuzumab combined adoptive cell therapy
3062 Background: Antitumor monoclonal antibody (mAb) is able to make molecular change in cancer cells and may also induce immune response via its Fc domain. CTLs selectively kill autologous tumor cells (AuTCs) is powerful for adoptive cell therapy of cancer. To investigate the immunological activity and anti-cancer effect in the combination therapy using the anti-HER2 Mab (trastuzumab, Tr) with adoptive cell therapy, a pilot clinical trial was performed for patients (pts) with refractory breast cancer. Methods: Fourteen pts with recurrent breast cancer were enrolled, they all had failed the conventional chemoradiotherapy. MLTC was performed using PBMC and primary- cultured AuTCs for 7–14 days. The generated cells were analyzed by Flow Cytometry, and the cytokine production and killing activity were evaluated by the ELISA and 51Cr-release assay. The cells were administrated by intra-peritumoral injection biweekly and Tr (2mg/kg) was infused every week. The treatments were repeated for 6 to 22 injections, and the total numbers of administered T cells were reached to ∼5.6 x 109. To assess the mechanism of Tr-effects, the antigen-loaded dendritic cells (DC) were examined in the phenotype, cytokine productions, and the ability to induce HER2 specific T cells in vitro. Results: After ∼ 2 weeks of MLTC, the derived cells, containing a preponderance of CD3+CD4+ or CD8+ T cells and CD56+ NK cells, showed significant degrees of cytotoxicity and IFN-γ production against AuTCs and HLA-matched allogenic tumor cell lines in 4 cases tested. The clinical response showed PR/SD/PD was 1/6/7 and adverse effect was tolerable. The tumor marker proteins (CEA, etc) were decreased in 5 pts. The carcinomatous pleural effusion was well controlled in 6 pts. In DC experiments, Tr-opsonized antigen-loaded DC enhanced the ability to induce CD8+ T cells specific for HER2-peptides in IFN-γ ELISPOT assay. Conclusions: Clinical responses were observed in pts with refractory breast cancer after receiving the adoptive cell therapy plus Tr. Our results suggested that the efficacy of immunotherapy might be augmented by anti-Her2 mAb, and it might be in part due to the involvement of mAb in the ability of DC cross-presentation followed by the enhancement of antitumor cellular immunity. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 3062
Strategy to augment the efficacy of immunotherapy for refractory breast cancer using trastuzumab combined adoptive cell therapy
3062 Background: Antitumor monoclonal antibody (mAb) is able to make molecular change in cancer cells and may also induce immune response via its Fc domain. CTLs selectively kill autologous tumor cells (AuTCs) is powerful for adoptive cell therapy of cancer. To investigate the immunological activity and anti-cancer effect in the combination therapy using the anti-HER2 Mab (trastuzumab, Tr) with adoptive cell therapy, a pilot clinical trial was performed for patients (pts) with refractory breast cancer. Methods: Fourteen pts with recurrent breast cancer were enrolled, they all had failed the conventional chemoradiotherapy. MLTC was performed using PBMC and primary- cultured AuTCs for 7–14 days. The generated cells were analyzed by Flow Cytometry, and the cytokine production and killing activity were evaluated by the ELISA and 51Cr-release assay. The cells were administrated by intra-peritumoral injection biweekly and Tr (2mg/kg) was infused every week. The treatments were repeated for 6 to 22 injections, and the total numbers of administered T cells were reached to ∼5.6 x 109. To assess the mechanism of Tr-effects, the antigen-loaded dendritic cells (DC) were examined in the phenotype, cytokine productions, and the ability to induce HER2 specific T cells in vitro. Results: After ∼ 2 weeks of MLTC, the derived cells, containing a preponderance of CD3+CD4+ or CD8+ T cells and CD56+ NK cells, showed significant degrees of cytotoxicity and IFN-γ production against AuTCs and HLA-matched allogenic tumor cell lines in 4 cases tested. The clinical response showed PR/SD/PD was 1/6/7 and adverse effect was tolerable. The tumor marker proteins (CEA, etc) were decreased in 5 pts. The carcinomatous pleural effusion was well controlled in 6 pts. In DC experiments, Tr-opsonized antigen-loaded DC enhanced the ability to induce CD8+ T cells specific for HER2-peptides in IFN-γ ELISPOT assay. Conclusions: Clinical responses were observed in pts with refractory breast cancer after receiving the adoptive cell therapy plus Tr. Our results suggested that the efficacy of immunotherapy might be augmented by anti-Her2 mAb, and it might be in part due to the involvement of mAb in the ability of DC cross-presentation followed by the enhancement of antitumor cellular immunity. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 2581
The cell transfer immunotherapy of intra-arterial infusion for the patients with liver metastases of gastrointestinal and pancreas cancer
2581 Background: T cells stimulated in the presence of IL-2 and autologous tumor cells (AuTL) may have high potential for efficacy as cellular immunotherapy for the liver metastatic cancer using the intraarterial approach without increasing toxicity. Methods: Ten patients with liver metastases of recurrent gastricintestinal cancer (4 esophageal cancers, 1 gastric cancer, 2 colon cancers, 3 pancreas cancers) were enrolled in a pilot clinical trial. The PBMCs were obtained by leukopheresis and cultured approximate 2 weeks for activation. AuTLs were evaluated for CD markers (CD3, CD4, CD8 etc.) and cytokine production after culture. AuTL were infused though a reservior port system via hepatic artery 2x/month for 2–3 months.Results: Toxicity related to cell transfer therapy at all treatments was minimal. 1 patient had completed response (CR) for 5 months, 3 patients had partial responses (PR) for 12, 6 and 5 months, 2 patient had stable disease (SD) for 6 months and 4 patient had progressive disease (PD). After treatments, two of 6 patients who experienced PR disease had T cell clonality by testing their PBMC using T cell receptor beta chain PCR. In 4/10 and 8/10 patients, CD3+CD8+ T cells and CD56+ NK cells increased after 2-week culture, respectively. Conclusions: This study demonstrate that AuTL can be infused safely through hepatic artery with minimal toxicity. Infusions of AuTLs with high Th1 cytokine might be effective to the patients with refractory liver metastases of recurrent gastricintestinal or pancreas cancer. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 2581
The cell transfer immunotherapy of intra-arterial infusion for the patients with liver metastases of gastrointestinal and pancreas cancer
2581 Background: T cells stimulated in the presence of IL-2 and autologous tumor cells (AuTL) may have high potential for efficacy as cellular immunotherapy for the liver metastatic cancer using the intraarterial approach without increasing toxicity. Methods: Ten patients with liver metastases of recurrent gastricintestinal cancer (4 esophageal cancers, 1 gastric cancer, 2 colon cancers, 3 pancreas cancers) were enrolled in a pilot clinical trial. The PBMCs were obtained by leukopheresis and cultured approximate 2 weeks for activation. AuTLs were evaluated for CD markers (CD3, CD4, CD8 etc.) and cytokine production after culture. AuTL were infused though a reservior port system via hepatic artery 2x/month for 2–3 months.Results: Toxicity related to cell transfer therapy at all treatments was minimal. 1 patient had completed response (CR) for 5 months, 3 patients had partial responses (PR) for 12, 6 and 5 months, 2 patient had stable disease (SD) for 6 months and 4 patient had progressive disease (PD). After treatments, two of 6 patients who experienced PR disease had T cell clonality by testing their PBMC using T cell receptor beta chain PCR. In 4/10 and 8/10 patients, CD3+CD8+ T cells and CD56+ NK cells increased after 2-week culture, respectively. Conclusions: This study demonstrate that AuTL can be infused safely through hepatic artery with minimal toxicity. Infusions of AuTLs with high Th1 cytokine might be effective to the patients with refractory liver metastases of recurrent gastricintestinal or pancreas cancer. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16_suppl) , 775
The synergistic clinical effect of autologous tumor-stimulated T lymphocyte and herceptin on the immunotherapy of breast cancer
775 Background: To investigate a synergistic anti-cancer effect in the killing activity on human breast cancer cells and the clinical responses between the autologous tumor-stimulated T lymphocytes (AuTL) in combination with anti-HER2 Mab (Herceptin). Methods: AuTL were generated in vitro against primary-cultured autologous tumor cells incubated with peripheral blood lymphocytes (PBL). Six patients with recurrent breast cancer (3 HER2/neu +; 3 HER2/neu -)were enrolled in a pilot clinical trial and they all failed the conventional chemoradiotherapy. The cultured AuTLs and the cytokine productions were analyzed by Flow Cytometry and ELISA. The killing activity of the AuTLs was evaluated before each treatment. AuTLs were administrated into recurrent tumor directly by intra-peritumoral injection biweekly and Herceptin was infused systemically every week. The treatments were repeated for 6 to 11 injections in the patients. The mean total administered T cells were reached to 3.2 - 4.6 x 10 9, respectively. The dosage of Herceptin was 2mg/kg in each patient. Results: The cultured AuTLs containing a preponderance of CD3+ CD8+ T cells and CD56+ NK cells, expressed significant degrees of cytotoxicity in 4 of 6 cases. CD4+CD25+ T cells proliferated markedly after day 14. ADCC was enhanced in 4 of 6 cases. The cytokine production of TGF-b1 in the supernatant revealed a significant increase after day 14. The clinical response showed the carcinomatous pleural effusion was disappeared and well controlled in one pt and one pt with marked regression in injected field was observed. The tumor marker proteins (CEA, etc.) were also decreased significantly in 2 of 6 pts. The adverse effects of the immunotherapy were tolerable with grade 1∼2 infusion reaction in each patient and no cardiac dysfunction was observed. Conclusions: These results suggested the synergistic enhancement of antitumor effect could be induced between AuTLs and anti-HRE2 Mab (Herceptin). Clinical responses were observed in two pts with refractory recurrent breast cancer after receiving the intra-peritumoral AuTL injection plus Herceptin immunotherapy. Thus this immunotherapy will be applicable for the patients with breast cancer. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16_suppl) , 775
The synergistic clinical effect of autologous tumor-stimulated T lymphocyte and herceptin on the immunotherapy of breast cancer
775 Background: To investigate a synergistic anti-cancer effect in the killing activity on human breast cancer cells and the clinical responses between the autologous tumor-stimulated T lymphocytes (AuTL) in combination with anti-HER2 Mab (Herceptin). Methods: AuTL were generated in vitro against primary-cultured autologous tumor cells incubated with peripheral blood lymphocytes (PBL). Six patients with recurrent breast cancer (3 HER2/neu +; 3 HER2/neu -)were enrolled in a pilot clinical trial and they all failed the conventional chemoradiotherapy. The cultured AuTLs and the cytokine productions were analyzed by Flow Cytometry and ELISA. The killing activity of the AuTLs was evaluated before each treatment. AuTLs were administrated into recurrent tumor directly by intra-peritumoral injection biweekly and Herceptin was infused systemically every week. The treatments were repeated for 6 to 11 injections in the patients. The mean total administered T cells were reached to 3.2 - 4.6 x 10 9, respectively. The dosage of Herceptin was 2mg/kg in each patient. Results: The cultured AuTLs containing a preponderance of CD3+ CD8+ T cells and CD56+ NK cells, expressed significant degrees of cytotoxicity in 4 of 6 cases. CD4+CD25+ T cells proliferated markedly after day 14. ADCC was enhanced in 4 of 6 cases. The cytokine production of TGF-b1 in the supernatant revealed a significant increase after day 14. The clinical response showed the carcinomatous pleural effusion was disappeared and well controlled in one pt and one pt with marked regression in injected field was observed. The tumor marker proteins (CEA, etc.) were also decreased significantly in 2 of 6 pts. The adverse effects of the immunotherapy were tolerable with grade 1∼2 infusion reaction in each patient and no cardiac dysfunction was observed. Conclusions: These results suggested the synergistic enhancement of antitumor effect could be induced between AuTLs and anti-HRE2 Mab (Herceptin). Clinical responses were observed in two pts with refractory recurrent breast cancer after receiving the intra-peritumoral AuTL injection plus Herceptin immunotherapy. Thus this immunotherapy will be applicable for the patients with breast cancer. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14) , 2541
Repeated immune cell transfer therapy combined with non myeloablative chemotherapy in patients with refractory recurrent gastrointestinal and lung cancer
2541 Background: Autologous tumor cells stimulated T lymphocytes (AuTL) were generated ex vivo from peripheral blood lymphocytes (PBL) over a two week co-culturing process and they may have potential for efficacy as a cellular immunotherapy (IT) in refractory gastrointestinal and lung cancer patients (pts). We investigated the feasibility of a combination of AuTL transfer and chemotherapy (ChT) with S1or ZD1839 (Iressa) conditioning regimen in order to take advantage by both the anticancer and lymphodepleted effects for reconstruction of antitumor immune followed by AuTL transfer as well as an adoptive IT. Method: 13 patients were enrolled in a pilot clinical trial. The two administrations of AuTL were given prior to one ChT for one treatment cycle. The treatment was repeated at least three cycles with a one-week interval. The nonmyeloablative ChT regimen was based on standard dose of S-1 for pts with gastric (4 pts), colon (4 pts) or esophageal (3 pts) cancer and of ZD1839 for 2 pts with lung adenocarcinoma. AuTLs were administered 1x/2weeks using IV for lung cancer and direct injection or IA for gastrointestinal cancer. Results: The median period of treatment was over 12.6 months and median survival time is 14.8 months. Adverse events related to both of the ChT and AuTL transfer were minimal. 4 of 13 pts achieved major tumor responses (2 CR: complete regression and 2 PR: partial regression). 3 pts had progressive disease (PD). 6 pts had stable disease (SD) for over 90 days. PBLs were evaluated for cytokine production prior to treatment and after 3 treatments. After treatment, three of 4 CR/PR pts had increased IFN-g or TNF-a production. Two of 6 SD pts had high IFN-g and TNF-a responses. TGF-b1 and IL-4 secretion increased simultaneously in 3/3 PD pts. Conclusions: These results show that combination therapy of AuTL transfer and non-myeloablative ChT is a feasible option for pts with refractory cancers. Using the synergistic mechanism of IT and ChT, a more stringent clinical evaluation of AuTL transfer combined with nonmyeloablative ChT should be performed for various cancer to improve the effect of this new approach. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14) , 2541
Repeated immune cell transfer therapy combined with non myeloablative chemotherapy in patients with refractory recurrent gastrointestinal and lung cancer
2541 Background: Autologous tumor cells stimulated T lymphocytes (AuTL) were generated ex vivo from peripheral blood lymphocytes (PBL) over a two week co-culturing process and they may have potential for efficacy as a cellular immunotherapy (IT) in refractory gastrointestinal and lung cancer patients (pts). We investigated the feasibility of a combination of AuTL transfer and chemotherapy (ChT) with S1or ZD1839 (Iressa) conditioning regimen in order to take advantage by both the anticancer and lymphodepleted effects for reconstruction of antitumor immune followed by AuTL transfer as well as an adoptive IT. Method: 13 patients were enrolled in a pilot clinical trial. The two administrations of AuTL were given prior to one ChT for one treatment cycle. The treatment was repeated at least three cycles with a one-week interval. The nonmyeloablative ChT regimen was based on standard dose of S-1 for pts with gastric (4 pts), colon (4 pts) or esophageal (3 pts) cancer and of ZD1839 for 2 pts with lung adenocarcinoma. AuTLs were administered 1x/2weeks using IV for lung cancer and direct injection or IA for gastrointestinal cancer. Results: The median period of treatment was over 12.6 months and median survival time is 14.8 months. Adverse events related to both of the ChT and AuTL transfer were minimal. 4 of 13 pts achieved major tumor responses (2 CR: complete regression and 2 PR: partial regression). 3 pts had progressive disease (PD). 6 pts had stable disease (SD) for over 90 days. PBLs were evaluated for cytokine production prior to treatment and after 3 treatments. After treatment, three of 4 CR/PR pts had increased IFN-g or TNF-a production. Two of 6 SD pts had high IFN-g and TNF-a responses. TGF-b1 and IL-4 secretion increased simultaneously in 3/3 PD pts. Conclusions: These results show that combination therapy of AuTL transfer and non-myeloablative ChT is a feasible option for pts with refractory cancers. Using the synergistic mechanism of IT and ChT, a more stringent clinical evaluation of AuTL transfer combined with nonmyeloablative ChT should be performed for various cancer to improve the effect of this new approach. No significant financial relationships to disclose.
- 1 October 2001
- Vol. 28 (11) , 1651-4
[Experimental gene therapy using p21/WAF1 gene in esophageal squamous cell carcinoma--adenovirus infection and gene gun technology].
P21/WAF1 (p21) inhibits the activity of the cyclin/cdk complex and controls the G1 to S cell phase transition. In the present study, we used a recombinant adenoviral approach and gene gun technology to introduce p21 into esophageal cancer cells in order to assess the effect of p21 on cell growth. Infection with the p21 adenovirus (AdV) using gene gun technology resulted in inhibition of TE9 and KE3 cell growth. The levels of involucrin, which is a marker of squamous epithelium differentiation, markedly increased at 48 h and 72 h after p21 AdV infection in TE9 cells. These results indicate that p21 plays an important role in esophageal cancer cell proliferation. Overexpression of the p21 gene can inhibit cell growth and induce differentiation in esophageal cancer cells. p21 gene therapy may prove beneficial in the treatment of esophageal cancer.
- 1 October 2001
- Vol. 28 (11) , 1651-4
[Experimental gene therapy using p21/WAF1 gene in esophageal squamous cell carcinoma--adenovirus infection and gene gun technology].
P21/WAF1 (p21) inhibits the activity of the cyclin/cdk complex and controls the G1 to S cell phase transition. In the present study, we used a recombinant adenoviral approach and gene gun technology to introduce p21 into esophageal cancer cells in order to assess the effect of p21 on cell growth. Infection with the p21 adenovirus (AdV) using gene gun technology resulted in inhibition of TE9 and KE3 cell growth. The levels of involucrin, which is a marker of squamous epithelium differentiation, markedly increased at 48 h and 72 h after p21 AdV infection in TE9 cells. These results indicate that p21 plays an important role in esophageal cancer cell proliferation. Overexpression of the p21 gene can inhibit cell growth and induce differentiation in esophageal cancer cells. p21 gene therapy may prove beneficial in the treatment of esophageal cancer.